API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
IRL752 (pirepemat) is a first-in-class, small-molecule cortical enhancer & a 5HT7/Alpha-2 receptor antagonist. It is being evaluated in phase 2 clinical trials for the treatment of parkinson disease.
Lead Product(s): Pirepemat
Therapeutic Area: Neurology Product Name: IRL752
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2024
Details:
IRL752 (Pirepemat) is designed to improve balance and reduce falls and people living with Parkinson’s by strengthening nerve cell signalling in the prefrontal cortex via action at 5HT7 and alpha-2 receptors.
Lead Product(s): Pirepemat
Therapeutic Area: Neurology Product Name: IRL752
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
IRL752 (Pirepemat) is designed to improve balance and reduce falls and people living with Parkinson’s by strengthening nerve cell signalling in the prefrontal cortex via action at 5HT7 and alpha-2 receptors.
Lead Product(s): Pirepemat
Therapeutic Area: Neurology Product Name: IRL752
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023